BioSpace News Archive

Avectas announced that it has exclusively licenced from ONK Therapeutics (ONK) a Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy incorporating ONK’s proprietary Death Receptor (DR5) TRAIL variant for the treatment of B-cell malignancies.

VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, has received approximately $5.3 million in net proceeds calendar year to date as a result of the exercise of equity warrants.

Achieved First Quarter 2020 ONPATTRO ® Net Product Revenues of $66.7 Million with More Than 950 Patients on Commercial Product Worldwide – − Achieved First Quarter 2020 GIVLAARI ® Net Product Revenues of $5.3 Million with More Than 50 Patients on Commercial Product in the U.S. – – Completed New Drug Application and Filed Marketing Authorisation Application for Lumasiran, Advancing Another Alnylam Investigational RNAi Therapeutic toward Market

Spruce Biosciences , a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, today announced the appointments of Samir Gharib, MBA, CPA, as Chief Financial Officer (CFO), and Dasharatha Reddy, Ph.D., as Vice President, Pharmaceutical Development and Manufacturing. The appointments expand the expertise of Spruce’s leadership team as the company advan

Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today a change in the format of its Annual Meeting of Shareholders (“Annual Meeting”) from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic (COVID-19) and to support the health and well-being of the Company’s shareholders, employees and their families. As previously announced, the Annual M

CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment

NN, Inc., a diversified industrial company, announced that in response to the COVID-19 pandemic and the urgent need for personal protective equipment, Paragon Medical, a division of NN Life Sciences headquartered in Pierceton, Indiana, has designed and released an intubation shield for healthcare workers.

New leadership to guide the dental technology company’s expansion and commercialization